Skip to content
Clinical Trials
Pipeline
Target-HTN
About
Team
Careers
Investor Relations
Publications
News
Contact Us
Menu
Clinical Trials
Pipeline
Target-HTN
About
Team
Careers
Investor Relations
Publications
News
Contact Us
Lorundrostat Development Program
At Mineralys Therapeutics, we are focused on developing medicines to target diseases driven by abnormally elevated aldosterone.
Hypertension
CKD
uHTN = uncontrolled hypertension; rHTN = resistant hypertension; CKD = chronic kidney disease